Seeking Alpha

Bristol-Myers Squibb (BMY) said over the weekend that it has agreed to buy Inhibitex...

Bristol-Myers Squibb (BMY) said over the weekend that it has agreed to buy Inhibitex (INHX)  for $2.5B as it looks to boost its pipeline ahead of the loss of patent protection for its blood thinner Plavix. The $26/share bid is over double Inhibitex's $9.87 close on Friday despite its main drug, for hepatitis C, only being in mid-stage trials. (PR)
Comments (1)
  • rytipu
    , contributor
    Comments (4) | Send Message
     
    Any details on when the deal will be completed? good arbitrage opportunity as there is >9% value between the last traded price and deal price of 26./share.
    10 Jan 2012, 04:02 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs